Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
n-acetyl glucose-dependent insulinotropic polypeptide
- Development stage
- Preclinical
- Lead developer
- Ulster University
- Modality
- Peptides
- Administration
- Subcutaneous, Intraperitoneal
01
Overview
N-acetyl glucose-dependent insulinotropic polypeptide (Ac-GIP) is a synthetic, N-terminally modified analog of the native incretin hormone glucose-dependent insulinotropic polypeptide (GIP). By acetylating the N-terminal amino acid, the peptide becomes highly resistant to degradation by the enzyme dipeptidyl peptidase IV (DPP-IV), which normally inactivates native GIP within minutes. This modification significantly enhances its plasma stability, potency, and duration of action. Ac-GIP acts as a potent agonist at the gastric inhibitory polypeptide receptor (GIPR), stimulating insulin secretion in a glucose-dependent manner and improving glucose tolerance. It has been primarily investigated in preclinical research settings, notably by researchers at the University of Ulster, for the potential treatment of type 2 diabetes mellitus and obesity-related metabolic disorders, as well as for potential applications in neuroendocrine tumor imaging.
- Other names
- N-acetyl-gastric inhibitory polypeptide
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)
Beyond the preview
Go deeper on n-acetyl glucose-dependent insulinotropic polypeptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on n-acetyl glucose-dependent insulinotropic polypeptide.